AGEN - Agenus Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

1.91

+0.08 (+4.37%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	1.83
Open	1.85
Bid	1.50 x 1000
Ask	2.05 x 4000
Day's Range	1.82 - 1.95
52 Week Range	1.55 - 6.19
Volume	1,010,706
Avg. Volume	1,405,225

Market Cap	216.369M
Beta	3.06
PE Ratio (TTM)	N/A
EPS (TTM)	-1.48
Earnings Date	Jul 28, 2017 - Jul 31, 2017
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	7.00

Trade prices are not sourced from all markets

All

News

Press Releases

Zacks11 hours ago
Agenus Receives Milestone Payment of $5 Million from Incyte
Agenus (AGEN) receives a milestone payment of $5 million from Incyte on the initiation of a phase I study of INCAGN2385.
PR Newswire2 days ago
Agenus Receives Milestone Payment from Incyte
LEXINGTON, Mass., Sept. 17, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced today receipt of a cash milestone from Incyte for the initiation of a Phase 1 clinical trial of INCAGN2385, an anti-LAG-3 antibody discovered by Agenus. Based on this milestone and under the terms of the agreement, Agenus received a $5 million payment and is eligible to receive up to an additional $505 million in potential development, regulatory and commercial milestones from Incyte. "This is the fourth antibody from our partnered programs that has advanced into clinical trials, once again proving our commitment to deliver on our existing partnerships," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus.
Zacks5 days ago
Implied Volatility Surging for Agenus (AGEN) Stock Options
Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.
Market Realist6 days ago
Analysts Still Bullish about BioLife Solutions
BioLife Solutions (BLFS) generated a net income of $1.05 million in the second quarter compared to a net loss of $768,212 in the second quarter of 2017. That translates to net income per share of $0.05 in the second quarter. Its net loss per share was $0.06 in the second quarter of 2017.
Motley Fool12 days ago
Why Agenus' Stock Perked Up in August
Agenus broke out of its year-long funk last month, but this rally might be short-lived. Here's why.
PR Newswire13 days ago
AgenTus Therapeutics to Present on the Anti-tumor Activities of Two Proprietary T Cell Receptors (TCRs) at CAR-TCR Summit in Boston, MA
- Both TCRs discovered by Novel "T-Rx™" Discovery Platform LEXINGTON, Mass. , Sept. 5 , 2018 /PRNewswire/ -- AgenTus Therapeutics, a subsidiary of Agenus Inc. (NASDAQ: AGEN), dedicated to advancing ...
PR Newswire15 days ago
Agenus to Present at The Annual B. Riley FBR Healthcare Conference in New York City
LEXINGTON, Mass. , Sept. 4, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies ...
Zacks19 days ago
Agenus (AGEN) Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Agenus Inc. (AGEN).
Thomson Reuters StreetEvents23 days ago
Edited Transcript of AGEN earnings conference call or presentation 9-Aug-18 12:30pm GMT
Q2 2018 Agenus Inc Earnings Call
Motley Fool27 days ago
Is Agenus Inc. Stock a Buy?
Agenus' stock has been ripping higher this week, but that doesn't make it a strong buy.
Zackslast month
Zacks.com featured highlights include: Dollar Tree, Agenus, Huntsman, ArcelorMittal and International Paper
Zacks.com featured highlights include: Dollar Tree, Agenus, Huntsman, ArcelorMittal and International Paper
Zackslast month
Step Beyond Bargain Hunting & Tap Rising P/E With 5 Stocks
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
PR Newswirelast month
Agenus Receives Second Milestone Payment from Merck
LEXINGTON, Mass., Aug. 15, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced today that Merck, known as MSD outside the United States and Canada, initiated a Phase I clinical trial of an undisclosed antibody candidate discovered by Agenus, under the two companies license and research collaboration. Based on this milestone and under the terms of the agreement, Agenus received a $4 million milestone payment and is entitled to receive up to an additional $95 million in success milestones from Merck. "We continue to deliver on all milestones with our existing partners." said Garo H. Armen, Ph.D., Chairman and CEO of Agenus.
Zackslast month
Agenus (AGEN) Delivering Well on Its Pipeline Candidates
We have issued an updated report on Agenus (AGEN) highlighting updates on its pipeline candidates.
Zackslast month
Agenus' (AGEN) Q2 Loss Narrower Than Expected, Revenues Beat
Agenus (AGEN) posts narrower-than-expected loss in the second quarter of 2018 and expects to file three investigational new drugs by the end of 2018.
Zackslast month
Agenus (AGEN) Reports Q2 Loss, Lags Revenue Estimates
Agenus (AGEN) delivered earnings and revenue surprises of 36.84% and -100.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Associated Presslast month
Agenus: 2Q Earnings Snapshot
On a per-share basis, the Lexington, Massachusetts-based company said it had a loss of 24 cents. The company's shares closed at $1.75. A year ago, they were trading at $3.85. _____ This story was generated ...
Zackslast month
Agenus (AGEN) Reports Narrower than Expected Loss in Q2
Agenus posts narrower than expected loss in the second quarter of 2018.
PR Newswirelast month
Agenus Reports Second Quarter 2018 Financial Results and Provides Corporate Update
- Cash milestones earned from Merck & Incyte - Three INDs filed and 3 more to be filed during 2018 - CTLA-4 & PD-1 trials treated more than 115 patients; clinical benefit confirmed LEXINGTON, Mass. , Aug. ...
ACCESSWIRElast month
Agenus Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Agenus Inc. (NASDAQ: AGEN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 8:30 AM Eastern Time. To listen ...
PR Newswire2 months ago
Agenus to Report Second Quarter 2018 Financial Results on August 9, 2018 and Host Conference Call and Webcast
LEXINGTON, Mass. , Aug. 2, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , ...
Zacks2 months ago
Will Agenus (AGEN) Disappoint Investors This Earnings Season?
In the second quarter of 2018, Agenus (AGEN) should focus on its pipeline candidates and provide updates on them as many of its pipeline candidates are under evaluation for various indications.
GlobeNewswire2 months ago
New Research: Key Drivers of Growth for Cadence Design, Agenus, Foundation Medicine, Honeywell International, NeoPhotonics, and Citrix — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, July 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cadence ...
Motley Fool2 months ago
Should Biotech Investors Fear Dilution?
Biotechs are infamous for tapping the public markets for capital on a regular basis. Here is a look at how this standard practice can both damage and create value for shareholders.
Benzinga2 months ago
Benzinga's Daily Biotech Pulse: Bellicum CFO Resigns, Roche's Trial Meets Endpoints, Avid Bioservices Turns To Black In Q4
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 16) Arcus Biosciences Inc (NYSE: RCUS ) BioLife Solutions Inc (NASDAQ: ...